Free Trial

908 Devices (NASDAQ:MASS) Raised to "Strong-Buy" at Leerink Partnrs

908 Devices logo with Medical background

Key Points

  • Leerink Partners upgraded 908 Devices from a "hold" rating to a "strong-buy" rating, with a new price objective of $12.00.
  • The stock currently holds a consensus rating of "Buy" and has an average target price of $8.00.
  • In recent insider trading, CFO Joseph H. Iv Griffith sold 6,940 shares, while Director Mark Spoto bought 10,000 shares, indicating mixed sentiment among company insiders.
  • Need Better Tools to Track 908 Devices? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

908 Devices (NASDAQ:MASS - Get Free Report) was upgraded by equities research analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating in a report released on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for 908 Devices' Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.61) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.37) EPS and FY2027 earnings at ($0.32) EPS.

Several other equities research analysts have also weighed in on MASS. Weiss Ratings reiterated a "sell (d-)" rating on shares of 908 Devices in a research note on Tuesday, July 29th. Leerink Partners upgraded 908 Devices from a "market perform" rating to an "outperform" rating and set a $12.00 price objective on the stock in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, 908 Devices presently has an average rating of "Moderate Buy" and an average target price of $8.00.

Get Our Latest Report on MASS

908 Devices Trading Down 1.4%

MASS traded down $0.09 on Tuesday, hitting $6.33. 194,319 shares of the stock traded hands, compared to its average volume of 301,155. 908 Devices has a 52 week low of $1.81 and a 52 week high of $8.06. The firm has a market capitalization of $226.99 million, a PE ratio of -11.72 and a beta of 0.37. The business has a fifty day moving average price of $6.88 and a two-hundred day moving average price of $4.95.

908 Devices (NASDAQ:MASS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). 908 Devices had a negative net margin of 30.54% and a negative return on equity of 24.30%. The firm had revenue of $4.70 million for the quarter, compared to the consensus estimate of $12.17 million. On average, equities research analysts forecast that 908 Devices will post -1.99 EPS for the current fiscal year.

Insider Transactions at 908 Devices

In other news, insider Michael S. Turner sold 16,082 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $7.51, for a total value of $120,775.82. Following the transaction, the insider directly owned 8,521 shares of the company's stock, valued at $63,992.71. The trade was a 65.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Spoto bought 10,000 shares of 908 Devices stock in a transaction dated Wednesday, May 14th. The stock was acquired at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the acquisition, the director directly owned 62,971 shares in the company, valued at $270,145.59. This represents a 18.88% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 31,543 shares of company stock valued at $233,890 in the last three months. 23.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MASS. Bank of New York Mellon Corp lifted its holdings in 908 Devices by 4.0% during the 1st quarter. Bank of New York Mellon Corp now owns 51,915 shares of the company's stock worth $233,000 after buying an additional 1,985 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of 908 Devices by 49.7% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,558 shares of the company's stock valued at $47,000 after buying an additional 2,176 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of 908 Devices by 453.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,784 shares of the company's stock valued at $27,000 after buying an additional 3,100 shares in the last quarter. American Century Companies Inc. increased its position in shares of 908 Devices by 10.8% in the 1st quarter. American Century Companies Inc. now owns 45,814 shares of the company's stock valued at $205,000 after buying an additional 4,471 shares in the last quarter. Finally, Hsbc Holdings PLC increased its position in shares of 908 Devices by 32.2% in the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company's stock valued at $46,000 after buying an additional 5,112 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

908 Devices Company Profile

(Get Free Report)

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

Further Reading

Should You Invest $1,000 in 908 Devices Right Now?

Before you consider 908 Devices, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 908 Devices wasn't on the list.

While 908 Devices currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines